Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions

Combination therapy with bosentan and phosphodiesterase-5 inhibitor in pulmonary arterial hypertension

A. H. Morice, S. Mulrennan, A. Clark
European Respiratory Journal 2005 26: 180; DOI: 10.1183/09031936.05.00030405
A. H. Morice
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S. Mulrennan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. Clark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

To the Editors:

Hoeper et al. 1 have produced an interesting report of their clinical experience of combined therapy with bosentan and sildenafil in patients with idiopathic pulmonary arterial hypertension. Whilst it is true that the relatively scant literature supporting the use of phosphodiesterase-5 inhibitors is centred around sildenafil, its relatively short duration of action requires the use of a thrice-daily regime. This has significant implications for compliance and, since treatment is continual, has large implications in the cost of treatment. It would be more logical to use a long-acting phosphodiesterase-5 inhibitor, and, with the advent of tadalafil, once-daily treatment becomes possible.

Here, we report our experience with a combination of bosentan and tadalafil in a 42-yr-old male with idiopathic pulmonary hypertension who had documented poor compliance with nebulised iloprost. Sildenafil 25 mg t.d.s. was added to bosentan, following a clinical deterioration and the finding of an estimated pulmonary artery systolic pressure of 130 mmHg, and this caused a fall in pulmonary artery pressure to 50 mmHg. Treatment with sildenafil was stopped 1 month later at another centre, and the pulmonary artery systolic pressure increased to 100 mmHg. Subsequently, sildenafil was restarted in combination with bosentan, and exercise tolerance doubled. After 3 months of combination treatment, the issue of compliance was raised by the patient and it was decided to substitute tadalafil 20 mg once daily for the sildenafil. The patient has continued on tadalafil for 9 months with an excellent symptomatic response. The last estimated pulmonary artery pressure was 61 mmHg.

    • © ERS Journals Ltd

    References

    1. ↵
      Hoeper MM, Faulenbach C, Golpon H, Winkler J, Welte T, Niedermeyer J. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur Respir J 2004;24:1007–1010.
      OpenUrlAbstract/FREE Full Text
    PreviousNext
    Back to top
    View this article with LENS
    Vol 26 Issue 1 Table of Contents
    • Table of Contents
    • Index by author
    Email

    Thank you for your interest in spreading the word on European Respiratory Society .

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Combination therapy with bosentan and phosphodiesterase-5 inhibitor in pulmonary arterial hypertension
    (Your Name) has sent you a message from European Respiratory Society
    (Your Name) thought you would like to see the European Respiratory Society web site.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Print
    Alerts
    Sign In to Email Alerts with your Email Address
    Citation Tools
    Combination therapy with bosentan and phosphodiesterase-5 inhibitor in pulmonary arterial hypertension
    A. H. Morice, S. Mulrennan, A. Clark
    European Respiratory Journal Jul 2005, 26 (1) 180; DOI: 10.1183/09031936.05.00030405

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero

    Share
    Combination therapy with bosentan and phosphodiesterase-5 inhibitor in pulmonary arterial hypertension
    A. H. Morice, S. Mulrennan, A. Clark
    European Respiratory Journal Jul 2005, 26 (1) 180; DOI: 10.1183/09031936.05.00030405
    del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
    Full Text (PDF)

    Jump To

    • Article
      • References
    • Info & Metrics
    • PDF
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    More in this TOC Section

    • Prevalence of pulmonary embolism on hospital admission in COVID-19 patients: Is there a role for pre-test probability scores and home treatment?
    • Asthma admissions during the COVID-19 pandemic
    • Defining optimal fluoroquinolone exposure against M. tuberculosis
    Show more Correspondence

    Related Articles

    Navigate

    • Home
    • Current issue
    • Archive

    About the ERJ

    • Journal information
    • Editorial board
    • Reviewers
    • CME
    • Press
    • Permissions and reprints
    • Advertising

    The European Respiratory Society

    • Society home
    • myERS
    • Privacy policy
    • Accessibility

    ERS publications

    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS books online
    • ERS Bookshop

    Help

    • Feedback

    For authors

    • Instructions for authors
    • Submit a manuscript
    • ERS author centre

    For readers

    • Alerts
    • Subjects
    • Podcasts
    • RSS

    Subscriptions

    • Accessing the ERS publications

    Contact us

    European Respiratory Society
    442 Glossop Road
    Sheffield S10 2PX
    United Kingdom
    Tel: +44 114 2672860
    Email: journals@ersnet.org

    ISSN

    Print ISSN:  0903-1936
    Online ISSN: 1399-3003

    Copyright © 2021 by the European Respiratory Society